Rapid Assessment of Dermal Carcinogenicity Using rasH2 Mice
Assessment of carcinogenicity for pharmaceuticals delivered via the dermal route is currently performed via labor-intensive, two-year studies. The use of transgenic rodents such as the rasH2 mouse has significantly reduced the timeline and effort required for systemic carcinogenicity assessment. More rapid dermal carcinogenicity testing of pharmaceuticals and chemicals may also be possible with this model.
Rapid Dermal Carcinogenicity Testing
View an informative presentation by Dr. Ryo Inoue of the Central Institute for Experimental Animals. He shares the results of a 26-week bioassay and an ultra-short-term 8-week bioassay using rasH2 mice.
You’ll gain insight into how:
- Global rasH2 production is controlled to provide a high-quality study animal worldwide and overtime
- Regulatory authorities in different regions accept transgenic models for carcinogenicity testing
- Dermal carcinogenicity testing in rasH2 mice replicates findings from two-year assays
- Tips and tricks for getting these models to work in your institution
Researcher | Contract Research Service Department | Central Institute for Experimental Animals (CIEA)
Ryo Inoue, Researcher in the Contract Research Service Department at Central Institute for Experimental Animals (CIEA)Ryo received his master's degree in Medical Science from Mie University in Mie, Japan. Ryo is currently enrolled in a PhD program (Immunology) at Mie University for his PhD. During his master's degree, he studied the role of the blood coagulation system in allergic reactions and wrote his graduation thesis about it. He has been working in the Contract research service operating group division of the Central Institute for Experimental Animals (CIEA) in Kawasaki, Japan since 2012, where he is in charge of carcinogenic performance study of rasH2 mice. His division also conducts contract studies for pharmaceutical companies, startups and universities using NOG mice and common marmosets.